Enobosarm Shows Activity, Tolerability in ER+/HER2– Advanced Breast Cancer
March 8th 2024Findings from a phase 2 trial support the premise that activating the androgen receptor may elicit antitumor effects in patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative breast cancer.